—
C+
C+ The full Closelooknet — membership. Open the C+ overview

BioNTech SE (BNTX) — chart, structure and Closelooknet read

The Closelooknet read

BioNTech develops immunotherapies, best known for its mRNA-based vaccine against SARS-CoV-2. It also runs a broad oncology pipeline spanning lung, breast, colorectal and other solid tumours, alongside infectious-disease candidates for influenza, tuberculosis and malaria.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for BNTX, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index Euro-AI 50 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

Euro-AI 50 · as of 2026-11-04

DayWeekMonth3 months
BNTX+4.3%+3.1%−5.3%−0.5%
Euro-AI 50−0.8%−1.7%−5.7%—

Against the index: 4.8 pts ahead on the week, 0.4 pts ahead on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 46/100 · S&P 500 fund at 49, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-04
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 73th percentile of the window, -21.7% over 20 sessions. Factor regime → 2026-11-04
  • Sector × region Health care in US: +5.5% week · +13.5% month · +15.8% quarter · +29.7% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-04
  • Sovereign pressure Index -1.79 · down 2.53 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-04
How it trades on rate days beta 1.23 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How BNTX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.23 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), BioNTech SE moved 1.23% on average · correlation 0.25 · higher than 90% of US names
  • Beta, last 3 months 1.68 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.72% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.81% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against BNTX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — BioNTech SE

BNTX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
BioNTech develops immunotherapies, best known for its mRNA-based vaccine against SARS-CoV-2. It also runs a broad oncology pipeline spanning lung, breast, colorectal and other solid tumours, alongside infectious-disease candidates for influenza, tuberculosis and malaria. The company was founded in 2008 and is based in Mainz, Germany.
Where it sits in the stack
BioNTech carries no seat in our Rubin index and no layer assignment there; it belongs to the Healthcare sleeve of our universe rather than the AI build-out stack.
Who it is priced against
Closelooknet's peer group places it with scored Healthcare names based in the US, including argenx, Regeneron, Vertex and BeiGene; the market also names Pfizer, its partner on the COVID vaccine, as a comparison.
Why Closelooknet tracks it
It holds a seat in our Euro-AI 50 index and carries a Closelooknet score, strongest on valuation and weakest on quality; the diary records no quotes or mentions for it so far.
What the diary watches
Whether oncology trial readouts move the pipeline value the market has priced in, and whether the mRNA platform finds use beyond vaccines.

BioNTech SE (BNTX) trades on US exchanges, classified under Healthcare. Constituent of Euro-AI 50.

The Closelooknet company score reads 38/100 composite (momentum 47, quality 35, valuation 51) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Canaccord, 2026-08-31 · last print 2026-11-03

The Street on this name

Analyst actions and the latest print for BNTX from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Canaccord — target 136 from 142 Target cut to $136 from $142 (+33.2% to spot) 2026-08-31
  • Latest print EPS 1.99 against 0.76 expected — a +162.9% beat 2026-11-03

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What BNTX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 none reported
  • Share count +0.5% in FY2025 106 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-05

Quick answers

What is BioNTech SE (BNTX)?

BioNTech SE trades as BNTX on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-05.

Is BNTX in a Closelooknet index?

Yes — BioNTech SE is a constituent of Euro-AI 50, as of 2026-11-05.

What is BioNTech SE's Closelooknet composite score?

38 out of 100, with momentum 47, quality 35 and valuation 51 sub-scores, as of 2026-11-05. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does BNTX trade against its moving averages?

BioNTech SE trades 9.6% below its 50-day and 10.3% below its 200-day moving average (3.4% below its 20-day). As of 2026-11-03 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is BNTX doing against its Closelooknet index?

Over the past month BioNTech SE is −5.3% against −5.7% for the Euro-AI 50 — 0.4 points ahead of its index, as of 2026-11-04. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does BioNTech SE compare with its peers?

Against its peer group (Biotechnology · US), BioNTech SE (BNTX) sits 29.9% below its 52-week high, 9.6% below its 50-day average; Halozyme Therapeutics Inc (HALO) is 2.7% below, BeOne Medicines AG (ONC) is 2.8% below, argenx NV ADR (ARGX) is 13.2% below, as of 2026-11-03. Put any of them next to BNTX in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does BioNTech SE trade when bond yields rise?

Over the past year BioNTech SE had a beta of 1.23 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 90% of US names. On the 10 sessions in which long bonds fell most it moved −0.72% on average, against −0.74% for the S&P 500. As of 2026-11-04; The "How it trades on rate days" block on this page carries the lines.

What does BioNTech SE do?

BioNTech develops immunotherapies, best known for its mRNA-based vaccine against SARS-CoV-2. It also runs a broad oncology pipeline spanning lung, breast, colorectal and other solid tumours, alongside infectious-disease candidates for influenza, tuberculosis and malaria. The company was founded in 2008 and is based in Mainz, Germany. Closelooknet's peer group places it with scored Healthcare names based in the US, including argenx, Regeneron, Vertex and BeiGene; the market also names Pfizer, its partner on the COVID vaccine, as a comparison. (Company snapshot of 2026-09-17.)

Where does BioNTech SE sit in the AI build-out?

BioNTech carries no seat in our Rubin index and no layer assignment there; it belongs to the Healthcare sleeve of our universe rather than the AI build-out stack. It holds a seat in our Euro-AI 50 index and carries a Closelooknet score, strongest on valuation and weakest on quality; the diary records no quotes or mentions for it so far. (Company snapshot of 2026-09-17.)

Does BioNTech SE pay a dividend?

No cash distribution shows in BioNTech SE’s price series over the last three years. The share count rose 0.5% over the fiscal year. As of 2026-11-04; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on BioNTech SE recently?

The most recent analyst action on BioNTech SE on the Closelooknet wire is a price target by Canaccord on 2026-08-31 (target 136 from 142). 1 action on the analyst wire since 2026-08-13: 1 target change. Its latest earnings print on the wire, 2026-11-03: EPS 1.99 against 0.76 expected — a +162.9% beat. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for BNTX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

same Closelooknet index seat first, then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.